Johnson Matthey Catalysis and Chiral Technologies Expands Ligands Offer; Boosts Buchwald Ligands Manufacturing to Commercial Scale

Johnson Matthey Catalysis and Chiral Technologies Expands Ligands Offer; Boosts Buchwald Ligands Manufacturing to Commercial Scale

WEST DEPTFORD – August 13, 2013 – Johnson Matthey (LSE: JMAT) has announced that their globalCatalysis and Chiral Technologies technology business unit, JMCCT, which provides trusted expertise in heterogeneous, homogeneous, chiral and biocatalytic technologies for customers in the pharmaceutical, fine chemical and agrochemical industries, is expanding its existing specialty ligand manufacturing capability to include commercial-scale manufacturing up to 100 kilograms. The company has a diverse specialty ligands portfolio, and this expansion is largely focused on the Buchwald ligands from the Massachusetts Institute of Technology for customers throughout Europe, Asia and the United States.

"The ability to offer Buchwald ligands from research through to commercial scale creates a unique, global position in the market that complements Johnson Matthey's wide range of catalyst technologies," commented Daren Bryce, Commercial Manager at Johnson Matthey Catalysis and Chiral Technologies. "Through our development, scale-up and manufacturing initiatives, Johnson Matthey is committed to providing the highest quality ligands that deliver value and efficiency to our customers."

The Buchwald ligands offered by JMCCT are a class of bulky and electron-rich dialkylbiaryl monophosphine ligands, which are used for the in situ generation of active catalysts. These ligands are used for coupling reactions in the manufacture of both pharmaceuticals and specialty chemicals and are more commonly offered at a research scale for use in the laboratory.

The expansion will also complement JMCCT initiatives to continually create a stronger global supply chain. As Bryce further noted, "Three separate expansion investments have now been made, focused on a new facility in Taloja, India last year and further expansion underway in Royston, UK."

To learn more about the JMCCT product and service offering, please visit: http://jmcct.com/products-services

 

Launch Readiness

Optimize cross-functional collaboration and engage with key stakeholders for the successful launch of a product

Join the Launch Readiness for Medical Affairs & Communications Teams Summit to learn best practices in taking a structured approach to enhance medical affairs activities surrounding a launch and increase knowledge and communication with thought leaders.